22 results about "Multiple tumor" patented technology

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

Provided are a jellyfish polypeptide, and a preparation method therefor and a use thereof. The jellyfish polypeptide provided by the present disclosure or a jellyfish polypeptide obtained by using the preparation method provided by the present disclosure exhibits a significant inhibitory effect on multiple tumors including colorectal cancer, lung cancer and prostate cancer, and also has a regulating function on mammalian immune systems.

The application discloses a classification method and device for pancreatic neuroendocrine tumors. The classification method comprises the following steps: segmenting tumor masks from enhanced CT images; for each tumor mask, generating a first peritumoral region and a second peritumoral region; dividing the tumor into multiple habitats for each tumor mask; extracting 3D radiomics features, multiple peritumoral microenvironment features, multiple tumor habitat features, multiple local pathological features and multiple global context features; selecting multiple target features for each enhanced CT image and calculating a radiomics score; inputting the radiomics score and clinical variables into a logistic regression model for training to obtain a trained logistic regression model; and using the trained logistic regression model to classify the enhanced CT images to be classified. The application can quickly and accurately realize G-grade classification of pancreatic neuroendocrine tumors, and provides a reliable non-invasive evaluation tool for clinical decision-making.

The present application relates to a kind of anti-CD276 nanobody, the anti-CD276 nanobody includes complementary determining region CDR and framework region FR;Wherein, the complementary determining region CDR includes complementary determining region CDR1-CDR3;The framework region FR includes framework region FR1-FR5.The anti-human CD276 nanobody provided by the present application has the immunoreaction characteristic with CD276 antigen, and specificity is good, and affinity is high, can be applied to the preparation of CD276 detection reagent or antitumor drug etc., the anti-human CD276 nanobody provided by the present application can be used as the antigen recognition domain of CAR Then the construction of CAR-T cell, it has significant killing effect to the multiple tumor cell lines of expression CD276 antigen;The anti-human CD276 nanobody provided by the present application can be used to detect the expression of CD276 in tumor tissue.

The invention relates to the technical field of image processing, in particular to an ultrasonic image ovarian tumor intelligent classification method, device and equipment and a medium. According to the method, the multiple tumor features are merged according to the similarity among the tumor features of the multiple ultrasonic images to obtain the redundancy-removed features, then the O-RADS score of the tumor is obtained based on the redundancy-removed features, and the O-RADS score comprises five scores, so that the lesion degree of the tumor can be more refined, and the evaluation result of the lesion degree of the tumor is improved. In addition, according to the method, the tumor features of each ultrasonic image are extracted separately, and then the final O-RADS score is obtained according to the tumor features of the multiple ultrasonic images. No matter how many ultrasonic images of a tumor are collected, the feature of each ultrasonic image can be independently extracted, and no matter how many tumor features are, an O-RADS score can be obtained, so that the collected ultrasonic images are not limited by evaluating the lesion degree of the tumor based on the O-RADS score, and the accuracy of evaluating the lesion degree of the tumor based on the O-RADS score is improved. Therefore, more ultrasonic images are allowed to be used for evaluating the tumor lesion degree, and the tumor lesion degree evaluation precision is further improved.

The small molecule antibody conjugate MAH-Rg3 is characterized in that a single-chain antibody MAH and ginsenoside Rg3 are coupled to form the conjugate MAH-Rg3, the amino acid sequence of the single-chain antibody MAH is shown as SEQ ID NO.1, and the structural formula of the antibody conjugate MAH-Rg3 is shown in the specification. The antibody MAH is connected with ginsenoside to form an MAH-Rg3 conjugate, the molecular weight of the MAH-Rg3 conjugate is as small as 33ka, the MAH-Rg3 conjugate can more easily penetrate blood vessels to directly reach the surfaces of tumor cells, the MAH-Rg3 conjugate is used in the growth inhibition process of the tumor cells, the strong inhibition effect on multiple tumor cells with positive HER2 expression is achieved, the tumor growth inhibition effect is achieved within 24 hours, and the application prospect is wide. According to the present invention, with the application of the MAH-Rg3, the better tumor cell growth inhibition ability can be obtained by prolonging the action time under the same dose, such that the use dose of the Rg3 and other components is reduced, the use range of the MAH-Rg3 is expanded, and the ginsenoside is precisely delivered in the targeting manner through the MAH-Rg3 having effects through the two ways so as to achieve the excellent anti-tumor effect.

The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and / or that employ a particular bioreactor having a gas permeable membrane.

This invention provides a continuous implantation device for PDX model tumor tissue, comprising: a main cannula; and a pushing component disposed at one end of the main cannula. The continuous implantation device for PDX model tumor tissue provided by this invention utilizes the cooperation of structures such as the main cannula, the pushing component, the tissue sampler, and the retaining spring. The tissue sampler can be pre-loaded with multiple tumor tissue blocks, the retaining spring enables precise positioning and switching of the tissue sampler, the pushing component can sequentially push the tissue blocks for implantation, and the main cannula can be externally connected to an syringe to achieve simultaneous delivery of gel and tissue blocks. This device enables continuous implantation of tumor tissue blocks without the need for repeated clamping and transfer operations, significantly improving implantation efficiency and avoiding the decrease in activity caused by prolonged exposure of tissue blocks outside the body. Furthermore, it eliminates the need for clamping tissue blocks during transfer, reducing the risk of mechanical damage and ensuring the integrity of the tissue blocks. It also enables simultaneous delivery of tissue blocks, gel, and drugs, improving the experimental adaptability of the device.

The invention discloses a cell culture device for tumor immunotherapy, which comprises a box body, a bin door rotationally connected to one end of the box body, a pushing mechanism arranged in the box body, and a clamping mechanism arranged on one side of the pushing mechanism, a lead screw A rotates to drive a lifting frame to ascend and descend, a servo motor A drives an electromagnet block to ascend and descend, tumor immunotherapy cell culture dishes at different positions are selected, the electromagnet block generates magnetic force when powered on to magnetically adsorb an iron plate, and a lateral electric push rod can pull back a storage plate under the magnetic adsorption effect. According to the cell culture device for the tumor immunotherapy, the tumor immunotherapy cell culture dishes at different positions are automatically loaded, manual taking is replaced, the multiple tumor immunotherapy cell culture dishes can be automatically taken in the cell culture process of the cell culture device for the tumor immunotherapy, the tumor immunotherapy cell culture dishes are prevented from sliding off and being broken, and the cell culture efficiency is improved. The automation degree of the cell culture device for tumor immunotherapy is improved.

The invention relates to a bionic intelligent microneedle tumor vaccine as well as a preparation method and application thereof. According to the vaccine, coaxial electrostatic spraying is utilized to construct a drug-loaded microsphere with a core-shell structure, the drug-loaded microsphere is coated with cancer cell-derived membrane protein, and then the drug-loaded microsphere is fixed at the needle point part of a soluble microneedle in a centrifugal manner, so that local drug delivery of crossing a cuticle layer and accurately delivering the drug-loaded microsphere to a corium layer is realized. The microsphere can load demethylated drugs DAC and TAM at the same time, and realizes responsive controlled release in a tumor microenvironment. A plurality of tumor-associated antigens and apoptosis-associated injury-associated molecular patterns carried by the cancer cell membrane protein can promote the maturation of dendritic cells and activate the specific T cell mediated anti-tumor immune response. In conclusion, the microneedle vaccine system integrates multiple functions of precise delivery, controllable release, chemical kinetics treatment, epigenetic regulation, immune activation and the like, the anti-tumor immunotherapy effect can be effectively enhanced, and a new strategy is provided for tumor immunotherapy.

The present invention relates a method for preparing a personalized tumor vaccine using magnetic induction hyperthermia (MIH) inactivation technique, falling within the field of medicine. In this method, a MIH nanoagent is used to generate localized heat within tumor cells upon exposure to an alternating magnetic field, triggering immunogenic cell death and inducing the emergence of neoantigens mutations in tumor cells. Depending on the specific requirements, two strategies can be utilized: one involves preparing a whole tumor cell vaccine containing multiple tumor antigens, while the other focuses on screening specific tumor neoantigens to create a targeted tumor neoantigen vaccine. Mouse model experiments demonstrated that the whole tumor cell vaccine prepared using this method effectively inhibited the growth of homologous tumors, with a tumor-free rate of 100% in the vaccination group. Using MIH for tumor cells inactivation offers several advantages, including the preservation of antigen integrity, enhanced antigen abundance, and an increase in the diversity and quantity of released endogenous adjuvants. All of these factors contribute to the creation of a highly immunogenic personalized tumor vaccine, which holds promise for inhibiting tumor growth, recurrence and metastasis.

The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and / or that employ a particular bioreactor having a gas permeable membrane.

The invention provides a tissue-type spheroid culture medium as well as a preparation method and application thereof. The culture medium comprises a basic culture medium, a plant-derived recombinant human serum albumin OsrHSA, a growth factor FGF-10, a low-oxygen simulation agent CoCl2 microcapsule, an inhibitor Rhosin, an antioxidant NAC, an antibiotic Plectasin, a targeted substitute peptide Tarextumab and a self-assembled scaffold (CultrexBME and / or RADA16-IKVAV), and the preparation method of the culture medium comprises the following steps: integrating thermosensitive components (a plant protein module, the inhibitor and the antibiotic) through a freeze-drying functional ball technology; and redissolving and assembling with a basic culture medium, and combining with a low-oxygen simulation agent microcapsule sustained-release system to form a gel-state culture medium. The culture medium is suitable for co-culture of various tumor cells and construction of an organoid model, and can accurately simulate a tumor microenvironment and improve the drug screening reliability.

The invention belongs to the technical field of medicines, and particularly relates to a diaryl substituted fused heterocycle compound as well as a preparation method and application thereof. The diaryl substituted fused heterocycle compound and the pharmaceutical salt thereof have excellent Tubulin / Katanin dual effects, multiple tumor cell proliferation inhibition activity and in-vivo antitumor activity, and can be applied to preparation of drugs for preventing or treating tumor-related diseases; the tumor-related diseases comprise benign and malignant tumors and other diseases caused by tumors.

The invention belongs to the technical field of immunology and biological medicine, and relates to application of CD28 CAR in substances for simultaneously killing plasma cell tumors and T cell tumors. The invention relates to application of CD28 CAR in preparation of substances for killing plasma cell tumors and T cell tumors, in particular to application in preparation or screening of CAR-T products with high safety, and the amino acid sequence of the CD28 CAR protein is shown as SEQ ID NO: 1. The CD28 CAR-T cell can safely and efficiently kill plasma cell tumors and T cell tumors at the same time, shows good amplification capacity, and does not generate a cell suicide phenomenon. According to the CAR-T cell immunotherapy, the problem of sib suicide is expected to be reduced, the killing efficiency of CAR-T cells is improved, the release of inflammatory factors is reduced, synchronous removal of various tumors is realized, key barriers of the CAR-T therapy in tumor immunotherapy are expected to be overcome, and a new hope of'healing 'is provided for patients with hematologic tumors and even solid tumors.

The present invention discloses a method for constructing a prediction model of the killing effect of NK cells on tumor cells, comprising: obtaining the killing effect of different NK cells on multiple tumor cells in a preset tumor category; constructing a data set according to the receptor expression profile of NK cells, the ligand expression profile of tumor cells and the killing effect; dividing the data set into a training set, a validation set and a test set; constructing a training model based on logistic regression; using the training set, the validation set and the test set to train, validate and test the training model in sequence, and using the training model that passes the test as the prediction model of the killing effect of NK cells on tumor cells. The prediction model of the killing effect of NK cells on tumor cells constructed by the present invention can effectively predict the killing effect of NK cells on tumor cells, which is conducive to selecting the most suitable NK cells for treatment according to the killing effect.

This invention relates to steroidal ketone compounds from *Echinops urinaria*, their extraction methods, and their antitumor applications. The structures of the steroidal ketone compounds are shown in Formula I. This invention studies the active components of *Echinops urinaria*, and has isolated several steroidal ketone compounds from its roots, two of which are newly discovered. Furthermore, the antitumor activity of the isolated steroidal ketone compounds has been studied, revealing that these compounds exhibit inhibitory activity against multiple tumor cell lines. This invention lays the foundation for in-depth research on the active components of *Echinops urinaria* and the development of new drugs.

The application provides an antitumor delphinine alkaloid in Caesalpinia minax, a core skeleton of angustifoline type, and provides an extraction method and application, and compound 3 is used for preparation of an antitumor drug. The natural delphinine with a new angustifoline type structural skeleton is obtained by separation and extraction, wherein compound 3 has a significant inhibitory effect on multiple tumor cell strains, and can be used for preparation of an antitumor drug.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.

The invention discloses an oncolytic agent-loaded STING activated microgel (OSAM) as well as a preparation method and application thereof. The oncolytic agent-loaded STING activated microgel (OSAM) is prepared by simply mixing hyaluronic acid microgel, an STING agonist and an oncolytic agent in a solution. The OSAM can continuously release an oncolytic agent and an STING agonist for 4 weeks, can induce significant up-regulation of MHC I and continuous activation of dendritic cells for more than one week, and can induce long-term stable activation of an STING pathway and direct lysis of tumor cells, so that various tumor specific antigens are generated, and long-acting and strong specific anti-tumor immunity is realized. Infiltration of cytotoxic T lymphocytes and natural killer cells can be remarkably promoted by injecting OSAM into a tumor for a single time. When the OSAM and the anti-CTLA-4 loaded microgel (C4M) are used in a combined manner, an excellent treatment effect is shown, and the cure rate reaches 71%. The oncolytic agent loaded STING activated microgel disclosed by the invention has the advantages of high safety, simplicity and convenience in preparation, strong immune activation capability and the like, and opens up a new way for the development of in-situ therapeutic tumor vaccines.

The invention relates to a bisbenzoquinone compound and a preparation method and application thereof.The bisbenzoquinone compound is separated from a fermentation product of chaetomium trilateral, has a brand-new chemical structure, has remarkable inhibitory activity on proliferation of multiple tumor cells, and reaches the nM-level inhibitory activity.

The invention provides a composition for intratumoral delivery, an anti-tumor vaccine and application thereof, and the intratumoral delivery carrier can realize in-situ delivery expression, simultaneously wrap mRNA, circRNA, siRNA, small molecule compounds and other drugs, and realize simultaneous delivery of a plurality of drugs. The multi-cytokine z therapeutic drug prepared by the method can realize in-vivo and in-vitro T cell activation, and has a remarkable anti-tumor effect in intratumor injection. The small nucleic acid medicine prepared by the method can realize in-vivo and in-vitro target gene knock-down, and the expression level of the target gene of tumor cells is obviously reduced after intratumor injection. The lipid nanoparticles of the intratumor delivery compound prepared by the method can kill multiple tumor cells in vivo and in vitro, have a remarkable anti-tumor effect after intratumor injection, have good prospects and practical value, and provide a new thought for development of intratumor treatment drugs in the field of tumor treatment.